Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2000 1
2002 1
2005 1
2006 3
2007 1
2008 2
2009 2
2010 3
2011 2
2012 4
2013 5
2014 6
2015 9
2017 9
2018 6
2019 8
2020 8
2021 6
2022 5
2023 14
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Personalized Management of Pheochromocytoma and Paraganglioma.
Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Nölting S, et al. Endocr Rev. 2022 Mar 9;43(2):199-239. doi: 10.1210/endrev/bnab019. Endocr Rev. 2022. PMID: 34147030 Free PMC article. Review.
A further 35% to 40% of Caucasian patients (a higher percentage in the Chinese population) are affected by somatic driver mutations. Thus, around 70% of all patients with pheochromocytoma/paraganglioma can be assigned to 1 of 3 main molecular clusters with different …
A further 35% to 40% of Caucasian patients (a higher percentage in the Chinese population) are affected by somatic driver mutations. Thus, a …
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.
Bellizzi AM. Bellizzi AM. Adv Anat Pathol. 2020 May;27(3):114-163. doi: 10.1097/PAP.0000000000000256. Adv Anat Pathol. 2020. PMID: 32205473 Free PMC article. Review.
Specific topics covered in this review include (1) broad tumor classification and associated screening markers; (2) the role of cancer epidemiology in determining pretest probability; (3) broad-spectrum epithelial markers; (4) noncanonical expression of broad tumor class screenin …
Specific topics covered in this review include (1) broad tumor classification and associated screening markers; (2) the role of cancer epide …
High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.
Jha A, Taïeb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru AH, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K. Jha A, et al. Clin Cancer Res. 2021 Jun 1;27(11):2989-2995. doi: 10.1158/1078-0432.CCR-20-3703. Epub 2021 Mar 8. Clin Cancer Res. 2021. PMID: 33685867 Free PMC article. Review.
Targeted radionuclide therapies (TRT) using (131)I-metaiodobenzylguanidine ((131)I-MIBG) and peptide receptor radionuclide therapy ((177)Lu or (90)Y) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma …
Targeted radionuclide therapies (TRT) using (131)I-metaiodobenzylguanidine ((131)I-MIBG) and peptide receptor radionuclide therapy ((177)Lu …
Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D, Juhlin CC, Falhammar H. Granberg D, et al. J Clin Endocrinol Metab. 2021 Apr 23;106(5):e1937-e1952. doi: 10.1210/clinem/dgaa982. J Clin Endocrinol Metab. 2021. PMID: 33462603 Free PMC article. Review.
EVIDENCE ACQUISITION: Extensive searches in the PubMed database with various combinations of the key words pheochromocytoma, paraganglioma, metastatic, malignant, diagnosis, pathology, genetic, and treatment were the basis for the present review. ...
EVIDENCE ACQUISITION: Extensive searches in the PubMed database with various combinations of the key words pheochromocytoma, parag …
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Ambrosini V, et al. Eur J Cancer. 2021 Mar;146:56-73. doi: 10.1016/j.ejca.2021.01.008. Epub 2021 Feb 12. Eur J Cancer. 2021. PMID: 33588146 Free PMC article. Review.
EANM Focus 3 reached consensus on employing (68)gallium-labelled somatostatin analogue ([(68)Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal ph …
EANM Focus 3 reached consensus on employing (68)gallium-labelled somatostatin analogue ([(68)Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT …
Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Szatko A, Glinicki P, Gietka-Czernel M. Szatko A, et al. Front Endocrinol (Lausanne). 2023 Jul 13;14:1204851. doi: 10.3389/fendo.2023.1204851. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37522121 Free PMC article. Review.
Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. ...
Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. ...
Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician.
Sharma S, Fishbein L. Sharma S, et al. Endocr Pract. 2023 Dec;29(12):999-1006. doi: 10.1016/j.eprac.2023.07.027. Epub 2023 Aug 15. Endocr Pract. 2023. PMID: 37586639 Review.
METHODS: A literature search of PubMed was carried out using key words, including pheochromocytoma, paraganglioma, treatment, diagnosis, screening, and management. ...
METHODS: A literature search of PubMed was carried out using key words, including pheochromocytoma, paraganglioma, treatment, …
Pheochromocytomas and Paragangliomas.
Tevosian SG, Ghayee HK. Tevosian SG, et al. Endocrinol Metab Clin North Am. 2019 Dec;48(4):727-750. doi: 10.1016/j.ecl.2019.08.006. Endocrinol Metab Clin North Am. 2019. PMID: 31655773 Review.
Hypertension is a critical and often dramatic feature of pheochromocytoma/paraganglioma, and its most prevalent reported symptom. ...This article summarizes current clinical approaches in patients with pheochromocytoma/paraganglioma....
Hypertension is a critical and often dramatic feature of pheochromocytoma/paraganglioma, and its most prevalent reported sympt …
90 results